Wedbush analyst Robert Driscoll lowered his price target for Paratek Pharmaceuticals to $12 from $17 following quarterly results. The analyst sees a measured launch ahead for Nuzyra, with momentum continuing toward an “ultimately successful” commercial launch of a differentiated antibiotic. He reiterates an Outperform rating on the shares.
https://thefly.com/landingPageNews.php?id=2906907
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.